Virtual GI Cancer Masterclass: Guidelines in mCRC
This webinar dives into guidelines in Metastatic Colorectal Cancer (mCRC), featuring a panel of renowned experts including chairperson, Prof Alberto Sobrero (Italy), with presentations from an esteemed faculty – Prof Per Pfeiffer (Denmark) and Dr Chiara Cremolini (Italy). The presentations are followed by a 20-minute Q&A session.
Join to learn about:
- Guidelines in mCRC
- How mCRC guidelines serve clinicians
- What the mCRC guidelines do not and cannot tell us
- How you would change the current version of the 2021 ESMO mCRC guidelines
More about the speakers:
- Prof Alberto SOBRERO (Italy)
Prof Alberto Sobrero has been the Head of the Medical Oncology Unit at Ospedale San Martino in Genoa, Italy, since 2001. His main research interests include gastrointestinal cancer treatment and the design and interpretation of clinical trials in oncology. Professor Sobrero has been the Chairman of the Protocol Review Committee of EORTC and has been a member of the scientific and educational committees of ASCO and ESMO, respectively. He was the recipient of the ESMO award in 2016.
- Prof Per PFEIFFER (Denmark)
Prof Per Pfeiffer, MD, PhD, is currently a Professor at the University of Southern Denmark and Senior Consultant at the Department of Oncology at Odense University Hospital in Denmark, and Head of the Center for Clinical Research which evaluate novel and unproven anti-cancer agents including molecular targeted therapies. His research interests include primarily clinical cancer research in patients with gastrointestinal cancer, primarily colorectal, gastric and pancreatic cancer.
- Dr Chiara CREMOLINI (Italy)
Dr Chiara Cremolini is an Assistant Professor in Medical Oncology at the University of Pisa (Italy). She has been particularly involved in trials investigating intensified chemotherapy regimens as upfront treatment of patients with metastatic colorectal cancer. With regard to translational activities, Dr Cremolini is mainly interested in the identification of molecular predictors of benefit from systemic treatments, and for this purpose has had close collaborations with numerous international institutions.